The session is a platform for CEO Tore Duvold to discuss the company's recent technical achievements, clinical evidence, and move towards commercial partnerships. The focus is on replacing estimation with evidence in the global fertility diagnostics market as they finalize Generation 3.0 and implement a partner-led strategy. The webcast is scheduled for Thursday, 26 March 2026, at 12:00 CET, in English and Swedish. Participants are encouraged to submit questions by 25 March 2026. Spermosens, a Swedish biotechnology company, specializes in fertility diagnostics, aiming to improve outcomes through innovative technologies like their product JUNO-Checked, which enhances precision in fertility evaluations. The company collaborates with research institutions and is listed on the Spotlight Stock Market as SPERM.

The session is a Q&A organized to allow shareholders and stakeholders to engage with the Company following the clinical validation of the JUNO-Checked system and its move towards commercial partnerships. This webcast aims to discuss the Company's position in the global fertility diagnostics market. Spermosens plans to make these Q&A sessions a regular event, usually held about a week after each quarterly report. The webcast is scheduled for Thursday, 26 March 2026, at 12:00 CET in English and Swedish, accessible via a provided link. Participants can submit questions in advance by emailing info@spermosens.com, with a deadline of 25 March 2026. Spermosens AB, a Swedish biotechnology company, focuses on fertility diagnostics, developing technologies to improve fertility outcomes. Their product, JUNO-Checked, enhances diagnostic precision by measuring sperm-egg binding capacity, aiding clinical decisions and treatment strategies. The company collaborates with research institutions and is listed on the Spotlight Stock Market as SPERM. More information can be found on their website.

The year-end report for Spermosens was initially omitted from a press release but is now available. Spermosens has achieved significant progress by focusing on evidence-based development of their diagnostic tool for male fertility, which addresses a major gap in reproductive healthcare. In 2025, they received patent approvals in several countries and made strides in partner-driven commercialization. Financially, the company reported no net sales, with an operating loss slightly improved from the previous year. They have a strong equity/assets ratio and liquidity ratio, with a notable increase in cash and cash equivalents. Significant events include patent approvals and partnerships to advance male fertility diagnostics. CEO Tore Duvold highlighted the company's unique technology and patent portfolio, emphasizing their progress in turning inventions into market-ready products. Their clinical study showed promising results for their JUNO-Checked diagnostic tool, which measures sperm's ability to bind to the egg. The company expanded its intellectual property and is working towards commercialization with partners in key markets. They secured strategic investments and are developing their Generation 3 system, aiming for completion in the first half of 2026. The focus remains on clinical validation and integration into fertility workflows, with the goal of creating long-term value for shareholders by addressing infertility challenges.

Spermosens has focused on transforming its invention into a viable product by emphasizing evidence-based development. In 2025, the company received patent approvals in several countries, including Canada, Mexico, Israel, and China. They also announced the outcome of warrant exercises and plans for commercialization. After the interim period, Spermosens signed Memoranda of Understanding with Sapyen and RSI to advance male fertility diagnostics. Financially, Spermosens reported no net sales for 2025, with an operating loss of SEK 9,201 thousand. Cash and cash equivalents increased significantly, and the equity/assets ratio improved to 95%. The company had four employees by the end of the period. CEO Tore Duvold highlighted the completion of a clinical study demonstrating the effectiveness of their diagnostic tool, JUNO-Checked, in addressing male infertility. The company expanded its intellectual property and is working towards commercialization with strategic partnerships. A strategic investment was secured in early 2025, supporting their mission to integrate technology into modern fertility practices. The development of their Generation 3 system is on track, aimed at improving throughput and ease of use, with completion expected in the first half of 2026. The focus remains on validating this system and advancing partnerships for commercialization.

Male fertility diagnostics face challenges related to sample quality and standardization. RSI has developed devices like the ProteX™ collection system and NovoSort® sperm processing technology to improve sperm quality and laboratory workflows. Spermosens and RSI have signed a non-binding Memorandum of Understanding (MoU) to evaluate how Spermosens' JUNO‑Checked can be integrated with RSI's devices to provide better clinical insights into male fertility. The MoU aims to assess technical compatibility, feasibility, and regulatory considerations in the US fertility care market. Spermosens seeks to introduce JUNO-Checked to clinics worldwide through partnerships. Tore Duvold, CEO of Spermosens, highlights the potential of JUNO‑Checked to enhance fertility diagnostics, while Sam Marple, CEO of RSI, notes the alignment of their technologies with clinical needs. Spermosens is a Swedish biotechnology company focused on fertility diagnostics, and RSI is a US-based medical device company specializing in sperm collection and preparation solutions.

Spermosens har fått ett patent beviljat i Kina, vilket stärker deras globala immaterialrättsliga portfölj som redan omfattar patent i flera viktiga marknader som Europa, USA, Japan och flera andra länder. Detta patent skyddar både metoden och systemet bakom deras JUNO-Checked-teknologi, vilket ger långsiktig exklusivitet för deras metod att bedöma spermiefunktion. Tore Duvold, VD för Spermosens, påpekar att Kina är en av världens största och snabbast växande fertilitetsmarknader med ett stort behov av förbättrade diagnostiska verktyg. Patentet i Kina är ett viktigt steg för att säkra deras immaterialrättsliga position för JUNO-Checked i en marknad med betydande klinisk aktivitet. JUNO-Checked är en diagnostisk teknologi som bedömer spermiernas förmåga att binda till JUNO-receptorn på ägget, vilket är ett viktigt steg i befruktningen. I Kina utförs över en miljon assisterade reproduktionsteknik-cykler årligen, och marknaden för fertilitetstjänster förväntas växa betydligt. Spermosens är ett bioteknikföretag baserat i Sverige som fokuserar på att förbättra fertilitetsdiagnostik. Deras produkt JUNO-Checked erbjuder en ny metod för att mäta spermie- och äggbindningskapacitet, vilket stödjer mer informerade kliniska beslut och individuella behandlingsstrategier. Företagets aktier är noterade på Spotlight Stock Market.

Between January 1st and September 30th, 2025, Spermosens achieved several milestones. During the third quarter, they provided a status update on their successful clinical study. Following the interim period, Spermosens received patent approvals in Israel, Mexico, and Canada. Financially, the company reported an operating loss for Q3 2025 of SEK 2,355 thousand, with no net sales, and ended the period with cash and cash equivalents of SEK 9,072 thousand. The equity/assets ratio was 97%, and the liquidity ratio was 927%. The company had four employees at the end of the period. CEO Tore Duvold commented on the year's achievements, highlighting the completion of a significant clinical study with their technology, JUNO-Checked, and the optimization efforts for market adaptation. The study demonstrated the potential of JUNO-Checked in assessing male fertility and diagnosing unexplained infertility. Spermosens is developing the third generation of JUNO-Checked to enhance speed and usability, with development taking place in a new laboratory in Lund. Patent approvals have been secured in major markets, and the company is actively seeking commercial partnerships, particularly in Europe and the United States, with ambitions to finalize agreements next year. The CEO expressed optimism about the progress and future developments.

Spermosens har fått ett patent i Israel som stärker deras immateriella rättighetsportfölj, vilken redan inkluderar patent i flera viktiga marknader som Europa, USA, Japan och andra länder. Skyddet täcker både metoden och systemet bakom deras JUNO-Checked teknologi, vilket ger långsiktig exklusivitet för deras metod att bedöma viktig spermiefunktion. VD Tore Duvold kommenterar att patentet i Israel är ett viktigt steg för deras globala IP-täckning, särskilt eftersom Israel är en strategiskt viktig marknad med en stark livsvetenskapssektor. JUNO-Checked är en diagnostisk teknologi som bedömer spermiernas förmåga att binda till JUNO-receptorn på ägget, en viktig del av befruktningen som inte kan bedömas med konventionella tester. Spermosens är ett bioteknikföretag i Sverige som fokuserar på att förbättra fertilitetsdiagnostik och utvecklar teknologier för att förbättra fertilitetsresultat. Deras produkt JUNO-Checked erbjuder en ny metod för att mäta spermie-äggbindning, vilket stödjer bättre kliniska beslut och individuella behandlingsstrategier. Företaget samarbetar med ledande forskningsinstitutioner och deras aktier är noterade på Spotlight Stock Market.